Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
General Internal Medicine
•
Myeloproliferative Neoplasms
•
Hematology
How do you manage and/or prevent ruxolitinib withdrawal syndrome?
Answer from: Medical Oncologist at Community Practice
Generally, tapering over a week or two is the best way to prevent it. If immediate discontinuation is needed, can consider using steroids.
Sign in or Register to read more
14673
Related Questions
What is your clinical threshold for treating a potential monoclonal gammopathy of thrombotic significance?
Would you change therapy for a CML patient in hematologic remission on imatinib found with positive qualitative BCR-ABL1 for the p230 protein?
What experience have you had with familial clustering of polycythemia vera?
How do you approach management for CCUS with severe cytopenias?
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?
Is there any evidence for amyloid/amyloidosis causing a spurious/false PSA reading?
For essential thrombocythemia with an indication for aspirin, would you defer therapy if they are on celecoxib?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
How do you decide between using ropeginterferon alfa-2b and peginterferon alfa-2a in MPN?
For patients with essential thrombocythemia already on prophylactic dose DOACs, do you defer starting aspirin?